162 related articles for article (PubMed ID: 18701842)
1. [Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer].
Fuzhong T; Nan L; Jiajia G; Miao L; Deqi Y
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1319-23. PubMed ID: 18701842
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
Tong F; Zhou B; Yang D; Cao Y; Liu P; Liu H; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1147-52. PubMed ID: 12145994
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Li X; Li Y; Yang SE; Ma Y; Wen SJ; Guo L; Guli KZ; Zhao B; Liu W; Hu X
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):916-20. PubMed ID: 22340101
[TBL] [Abstract][Full Text] [Related]
5. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Eralp Y; Keskin S; Akışık E; Akışık E; İğci A; Müslümanoğlu M; Yılmaz S; Tunacı M; Çamlıca H; Tuzlalı S; Saip P; Dalay N; Özmen V; Topuz E
Am J Clin Oncol; 2013 Jun; 36(3):215-23. PubMed ID: 22441341
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.
Fernández-Sánchez M; Gamboa-Dominguez A; Uribe N; García-Ulloa AC; Flores-Estrada D; Candelaria M; Arrieta O
Med Oncol; 2006; 23(2):171-83. PubMed ID: 16720917
[TBL] [Abstract][Full Text] [Related]
8. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.
Petrarca CR; Brunetto AT; Duval V; Brondani A; Carvalho GP; Garicochea B
Clin Breast Cancer; 2011 Apr; 11(2):129-34. PubMed ID: 21569999
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
10. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
11. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
Huang O; Chen C; Wu J; Chen S; Chen X; Liu G; Hu Z; Lu J; Wu J; Shao Z; Shen Z; Shen K
BMC Cancer; 2009 Oct; 9():375. PubMed ID: 19845944
[TBL] [Abstract][Full Text] [Related]
13. Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Sánchez-Rovira P; Antón A; Barnadas A; Velasco A; Lomas M; Rodríguez-Pinilla M; Ramírez JL; Ramírez C; Ríos MJ; Castellá E; García-Andrade C; San Antonio B; Carrasco E; Palacios JL
Clin Transl Oncol; 2012 Jun; 14(6):430-6. PubMed ID: 22634531
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
18. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.
Boidot R; Vegran F; Lizard-Nacol S
Int J Mol Med; 2009 Feb; 23(2):285-91. PubMed ID: 19148555
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
